Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FC-12738 is a novel synthetic retro-inverso pentapeptide based on thymopentin, developed by Neurodegenerative Disease Research for the treatment of neuroinflammation and amyotrophic lateral sclerosis (ALS). The drug is designed to regulate the cell danger response via innate immune pathways, aiming to modulate T cell responses and neuroinflammatory processes implicated in ALS. Preclinical studies have demonstrated favorable pharmacokinetic properties and safety profiles in animal models. In humans, early clinical data indicate a plasma half-life of approximately 2.4–2.5 hours—significantly longer than native thymopentin—and good tolerability with no significant adverse events reported so far[1][6][7][8]. The drug is administered subcutaneously.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on FC-12738.